Clinical oncology relies increasingly on biomedical imaging, with anatomical imaging, especially using CT and 1 H-MRI, forming the mainstay of patient assessment, from diagnosis to treatment monitoring. However, the need for further improvements in specificity and sensitivity, coupled with imaging techniques that are reaching their limit of clinically attainable spatial resolution, has resulted in the emergence and growing use of imaging techniques with additional functional readouts, such as 18 FDG-PET and multiparametric MRI. These techniques add a new dimension to our understanding of the biological behavior of tumors, allowing a more personalized approach to patient management.
An important functional imaging target in cancer is metabolism. PET measurements of 18 Fluorodeoxyglucose uptake ( 18 FDG-PET), a 18 F-labeled glucose analog, and 1 H-MRS measurements, have both been used to investigate tumor metabolism for diagnostic purposes. However, clinical applications of MRS have been hampered by low sensitivity and consequently low spatial and temporal resolution (1). Nuclear spin hyperpolarization of 13 C-labeled substrates, using dynamic nuclear polarization (DNP), which radically increases the sensitivity of these substrates to detection by 13 C MRS (2), has created a renewed interest in MRS measurements of tissue metabolism. Successful translation of this technique to the clinic was achieved recently with measurements of [1-
13 C]pyruvate metabolism in prostate cancer (3) (see Figure 1 ). We explore here the potential clinical roles for metabolic imaging with hyperpolarized [1-
13 C]pyruvate.
DYnAMiC nUCLEAR pOLARiZATiOn
Dynamic nuclear polarization, which can increase the signal-to-noise ratio in the solution-state 13 C MR experiment by 10 4 -to 10 5 -fold (4), has enabled in vivo imaging of various metabolites and their enzymatic conversion into other species, as well as metabolic fluxes in central metabolic pathways, such as glycolysis (5-7) and the tricarboxylic acid cycle (8-10). The principle limitation of the technique is the short half-life of the polarization; for [1-
13 C]pyruvate in vivo, this is typically between 30 and 40 s, which means that the hyperpolarized signal will last for 2-3 min. Therefore, the substrate, whose metabolism is to be imaged, must be transferred promptly from the polarizer, injected intravenously, and then transit quickly via the circulation to the tissue of interest, where it should be taken up and metabolized rapidly (11, 12 
pYRUVATE
Pyruvate is an important intermediate in many biochemical pathways (28). As an end product of glycolysis, pyruvate can be reduced by NADH to generate lactate, in the readily reversible reaction catalyzed by lactate dehydrogenase, or transaminated by glutamate, in the reversible reaction catalyzed by alanine aminotransferase (ALT), to form alanine. In tissues with high levels of mitochondrial activity, such as heart muscle, pyruvate may be irreversibly decarboxylated to form carbon dioxide in the reaction catalyzed by the mitochondrial pyruvate dehydrogenase (PDH) complex (26). Since increased aerobic glycolysis is a well-recognized hallmark of cancer (29, 30), this has made it an attractive pathway to probe for diagnostic and treatment monitoring purposes (3, 17, 31 (11), a defining feature of cancer metabolism, i.e., the failure to oxidize pyruvate in the presence of oxygen and reduce it instead to lactate (the "Warburg Effect"), this means that hyperpolarized [1-
13 C]pyruvate may be more specific for detecting cancer than 18 FDG-PET. The latter detects only elevated levels of glucose uptake, which is a feature of many normal tissues and cancer, for example, the brain. The specificity of cancer detection by hyperpolarized [1-
13 C]pyruvate may be confounded, however, by the presence of hypoxia, which will also lead to lactate accumulation and increased lactate labeling (38). Another drawback of imaging with hyperpolarized [1-
13 C]pyruvate is that the short half-life of the polarization precludes whole-body imaging.
Advantages Compared to 1 H MRS
1 H-MR spectroscopy and spectroscopic imaging measurements of tissue metabolite profiles are label-free and have found some applications, for example, in identifying different types of brain tumor (52). A notable example is the detection of 2-hydroxyglutarate, which can be used to identify glioblastomas with isocitrate dehydrogenase mutations (IDH) (53). 1 H MRSI has also proved to be important in the prostate, where it can improve the specificity of detection and determination of tumor extent when combined with other MR imaging sequences (54). However, detectable metabolites are present in only millimolar concentrations, as compared to tissue water protons, which are present at ~80M, which results in long data acquisition times and limited spatial resolution. In addition, data processing can be more complex and the biochemical information provided may be unfamiliar to many clinicians, which has limited routine clinical application. Moreover, 1 H MR spectroscopy and spectroscopic images of metabolite profiles provide a static picture of tumor metabolism. On the other hand, imaging with hyperpolarized 13 C-labeled substrates provides dynamic metabolic flux information in the form of images that can be acquired at relatively high spatial and temporal resolutions and therefore should provide an improved assessment of tumor behavior. Additionally, coinjection of different hyperpolarized substrates could also provide additional functional information in the same acquisition, e.g., pyruvate for assessing glycolytic activity and urea for assessing tumor perfusion (55). C-acetate, as a marker of fatty acid synthesis, and labeled glutamine, which can be used to assess glutaminolysis; both of which are upregulated in tumor cells (57, 58) . These PET probes may be especially useful in tumors where 18 FDG is ineffective, e.g., in prostate tumors (59) and in gliomas (60) , and where the corresponding hyperpolarized 
Liquid Biopsies
Blood and urine biomarkers, obtained from "liquid biopsies, " are also evolving, providing information in a non-invasive way allied to the advantages of collection simplicity and relatively low cost. Many body fluid biomarkers have been reported for different types of cancer; however, few have become established in the clinic, usually because they lack specificity. A recent promising example is a panel of three urine biomarkers for early detection of pancreatic cancer (65) . Rapid advances in DNA sequencing technology have allowed somatic mutations present in tumor cells to Metabolic Imaging with Hyperpolarized [1-
Frontiers in Oncology | www.frontiersin.org be detected and tracked in blood-borne circulating tumor DNA (ctDNA). These fragments of DNA, which have been detected with most types of cancer, have been demonstrated to have potential roles in early detection, staging, and in detecting response to therapy and acquired resistance to treatment (66, 67) . Although measurements with hyperpolarized 13 C-labeled cell substrates and these new circulating biomarkers are still their infancy it seems likely that they will provide complementary information, for example, in the assessment of tumor heterogeneity.
COnCLUSiOn AnD FUTURE DiRECTiOnS
Imaging with hyperpolarized 13 C-labeled cell substrates has the potential to become a powerful tool in many steps of clinical evaluation, allowing a more personalized approach to treatment. The first clinical trial established the feasibility of imaging human tumors with hyperpolarized [1-13 C]pyruvate. Since this substrate can be used to assess glycolysis, which is upregulated in many tumors, then this should make it a very general tool for oncological imaging in the clinic. Despite the biological insights that imaging with hyperpolarized 13 C-labeled substrates promises to deliver in the clinic, it will nevertheless have to prove itself against established and emerging clinical techniques, demonstrating that it can provide unique information that changes clinical practice.
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